Article
Identification of molecular and cytogenetic risk factors for unfavorable core-binding factor-positive adult AML with post-remission treatment outcome analysis including transplantation.
Bone marrow transplantation - 1 Dec 2014
Yoon J-H, Kim H-J, Kim J-W, Jeon Y-W, Shin S-H, Lee S-E, Cho B-S, Eom K-S, Kim Y-J, Lee S, Min C-K, Cho S-G, Lee J-W, Min W-S, Park C-W
Abstract excerpt
Emerging molecular studies have identified a subgroup of patients with unfavorable core-binding factor-positive (CBF)-AML who should be treated by intensified post-remission treatments. We analyzed 264 adults with CBF-AML from 2002 to 2011, and focused on 206 patients who achieved CR after standard '3+7' induction chemotherapy. Patients who achieved CR with an available donor were treated with allogeneic...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.